Originally dba Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), in March 2016, the firm changed its name to Biostage, Inc. and subsequently shifted to trading on OTC (OTC: BSTG). Working in the space of regenerative medicine, patient-specific stem cell therapy, and tissue engineering, the company develops customized bioengineered organ implants designed to restore organ function of the esophagus, trachea and bronchus damaged by disease or trauma. Biostage's bioengineered organ implants are based on the firm's Cellframe technology comprise of a biocompatible scaffold that is seeded with the recipient's own stem cells dedicated internal team of materials scientists, engineers and biologists, working with external collaborators, is addressing the life-threatening conditions of congential defects, trauma and cancers of the esophagus, bronchi and trachea. Even when they are available, current treatment can drastically and adversely impact quality of life while also having a significant mortality and morbidity rate. Biostage is developing radically new ways to treat these life-threatening conditions with clinical trials being designed to offer the potential of improved mortality rates, reduced complications, and enhanced patient quality of life.